The Contraction of the Human Pulmonary Artery by LTC4 is Resistant to CYSLT1 Antagonists and Counteracted by Prostacyclin Release

  • Magnus Bäck
  • Xavier Norel
  • Laurence Walch
  • Jean-Pierre Gascard
  • Sven-Erik Dahlén
  • Charles Brink
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 507)


The role of cysteinyl leukotrienes (cysLTs; LTC4LTD4 and LTE4) in asthma has been well established (Drazen et al., 1999). However, cysLTs also contract isolated human pulmonary vascular preparations (Schellenberg and Foster, 1984; Bourdillat et al., 1987; Labat et al., 1992; Ortiz et al., 1995) and have been proposed to be involved also in vascular pathologies, for example pulmonary hypertension (Stenmark et al., 1983). This suggestion has received support from animal studies (Davidson and Drafta, 1992) but the precise function of cysLTs in the pulmonary circulation remains to be established. Previous studies have raised support for at least two different receptors for cysLTs (Labat et al., 1992; Coleman et al., 1995; Bäck et al., 1996; Dahlén, 1998). Human bronchi contain CysLTI receptors (Buckner et al., 1986) that are targets for the clinically used anti-asthmatic CysLTI antagonists (Drazen et al., 1999). The receptor present on the human pulmonary venous smooth muscle is however resistant to CysLTI antagonists and

is referred to asCysLT 2 (Labat et al., 1992). This communication will report on cysLT effects in human pulmonary arterial preparationsin vitro.


Pulmonary Hypertension Pulmonary Circulation Primary Pulmonary Hypertension Human Airway Smooth Muscle Cell Human Bronchus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Back, M., Wikström Jonsson, E. and Dahlén, S.E., 1996, The cysteinyl-leukotriene receptor antagonist BAY u9773 is a competitive antagonist of leukotriene C, in the guinea-pig ileumEur J Pharmacol.317: 107.PubMedCrossRefGoogle Scholar
  2. 2.
    Bourdillat, B., Haye-Legrand, I., Labat, C., Raffestin, B., Norel, X., Benveniste, J. and Brink, C., 1987, Effects of various pharmacological agents on isolated human bronchial and pulmonary arterial and venous muscle preparations contracted by LTDFundam Clin Pharmacol.1:433.PubMedCrossRefGoogle Scholar
  3. 3.
    Buckner, C.K., Krell, R.D., Laravuso, R.B., Coursin, D.B., Bernstein, P.R. and Will, J.A., 1986, Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotrieneC4and leukotrieneD4. J Pharmacol Exp Ther.237:558.PubMedGoogle Scholar
  4. 4.
    Coleman, R.A., Eglen, R.M., Jones, R.L., Narumiya, S., Shimizu. T., Smith, W.L., Dahlén, S.E., Drazen, J.M., Gardiner, P.J., Jackson, W.T., Jones, T.R., Krell, R.D. and Nicosia, S., 1995, Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature.Adv Prostaglandin Thromboxane Leukot Res.23:283.PubMedGoogle Scholar
  5. 5.
    Dahlén, S.E., 1998, Leukotriene receptors: incompletely defined targets for treatment of asthma and inflammation, in:Five-lipoxygenase Products in AsthmaJ.M. Drazen, S.E. Dahlén, T.H. Lee, eds., Marcel Dekker, New York.Google Scholar
  6. 6.
    Davidson, D. and Drafta, D., 1992, Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4in the rat lungJAppl Physiol.73:955.Google Scholar
  7. 7.
    Drazen, J.M., Israel, E. and O’Byrne, P.M., 1999, Treatment of asthma with drugs modifying the leukotriene pathwayN Engl J Med.340:197.PubMedCrossRefGoogle Scholar
  8. 8.
    Gaine, S.P. and Rubin, L.J., 1998, Primary pulmonary hypertensionLancet352:719.PubMedCrossRefGoogle Scholar
  9. 9.
    Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A.W., Frenette, R., Gauthier, J.Y., Leger, S., Masson, P., McFarlane, C.S., Piechuta, H., Rokach, J., Williams, H., Young, R.N., DeHaven, R.N. and Pong, S.S., 1989, Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotrieneD4receptor antagonist,Can J Physiol Pharmacol.67:17.PubMedCrossRefGoogle Scholar
  10. 10.
    Krell, R.D., Aharony, D., Buckner, C.K., Keith, R.A., Kusner, E.J., Snyder, D.W., Bernstein, P.R., Matassa, V.G., Yee, Y.K., Brown, F.J., Hesp, B. & Giles, R.E., 1990, The preclinical pharmacology of ICI 204,219Am Rev Respir Dis.141:978.PubMedCrossRefGoogle Scholar
  11. 11.
    Labat, C., Ortiz, J.L., Nord, X., Gorenne, I., Verley, J., Abram, T.S., Cuthbert, N.J., Tudhope, S.R., Norman, P., Gardiner, P. and Brink, C., 1992, A second cysteinyl leukotriene receptor in human lung.J Pharmacol Exp Ther.263:800.PubMedGoogle Scholar
  12. 12.
    Ortiz, J.L., Gorenne, I., Cortijo, J., Seller, A., Labat, C., Sarria, B., Abram, T.S., Gardiner, P.J., Morcillo, E. and Brink, C., 1995, Leukotriene receptors on human pulmonary vascular endothelium.Br J Pharmacol.115:1382.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Panettieri, R.A., Tan, E.M., Ciocca, V., Luttmann, M.A., Leonard, T.B. & Hay, D.W., 1998, Effects of LTD, on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonistsAm J Respir Cell Mol Biol.19:453.PubMedCrossRefGoogle Scholar
  14. 14.
    Schellenberg, R.R. and Foster, A., 1984, Differential activity of leukotrienes upon human pulmonary vein and arteryProstaglandins27:475.PubMedCrossRefGoogle Scholar
  15. 15.
    Stenmark, K.R., James, S.L., Voelkel, N.F., Toews, W.H., Reeves, J.T. and Murphy, R.C., 1983, LeukotrieneC4andD4in neonates with hypoxemia and pulmonary hypertension,N Engl J Med.309:77.PubMedCrossRefGoogle Scholar
  16. 16.
    Walch, L., Labat, C., Gascard, J.P., de Montpreville, V., Brink, C. and Norel, X., 1999, Prostanoid receptors involved in the relaxation of human pulmonary vessels.Br J Pharmacol.126: 859.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Magnus Bäck
    • 1
  • Xavier Norel
    • 2
  • Laurence Walch
    • 2
  • Jean-Pierre Gascard
    • 2
  • Sven-Erik Dahlén
    • 1
  • Charles Brink
    • 2
  1. 1.Experimental Asthma & Allergy ResearchThe National Institute of Environmental MedicineStockholmSweden
  2. 2.Centre National de la Recherche Scientifique ESA 8078Centre Chirurgical Marie Lannelongue, 133, ave de la RésistanceLe Plessis RobinsonFrance

Personalised recommendations